AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. DSUVIA® (known as DZUVEO in Europe) and Zalviso® are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, for use in medically supervised settings. Co.'s portfolio includes ARX-02 Higher Strength Sufentanil Sublingual Tablet for cancer breakthrough pain in opioid-tolerant patients; and ARX-03 Combination Sufentanil/Triazolam Sublingual Tablet for mild sedation and pain relief during painful procedures in a physician's office. The ACRX stock yearly return is shown above.
The yearly return on the ACRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|